Login to Your Account

Morphosys pays $20M for Emergent's bispecific MAb outside N. America

By Cormac Sheridan
Staff Writer

Thursday, August 21, 2014

DUBLIN – Morphosys AG is taking a first step into bispecific antibody development by licensing ex-North American rights to Emergent Biosolutions Inc.'s cancer immunotherapeutic ES414, in return for $20 million up front and milestones totaling $163 million.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription